Proving the Concept: Aptevo Technology, Pipeline, to Exemplify the Speed and Power of Modular Biotherapeutics at Presentation
Proving the Concept: Aptevo Technology, Pipeline, to Exemplify the Speed and Power of Modular Biotherapeutics at Presentation
Aptevo's Peter Pavlik, PhD, to chair a session on "Bi and Multispecific Biologics" and will also give talk titled "Modular Multispecific Biotherapeutics: Rapid Therapeutic Design with the ADAPTIR Platform" at Cambridge Healthcare Institute's, Pep Talk 2025
Aptevo的彼得·帕夫利克博士将主持关于 “双特异和多特异性生物制剂” 的会议,还将在剑桥医疗研究所的Pep Talk 2025上发表题为 “模块化多特异性生物疗法:使用ADAPTIR平台进行快速治疗设计” 的演讲
SEATTLE, WA / ACCESSWIRE / November 26, 2024 / Aptevo Therapeutics ("Aptevo") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR and ADAPTIR-FLEX platform technologies, todayannounced that Peter Pavlik, PhD, Senior Director of Protein Engineering, will chair a "Bi and Multispecific Biologics" session and present a talk titled "Modular Multispecific Biotherapeutics: Rapid Therapeutic Design with the ADAPTIR Platform," at the Cambridge Healthcare Institute's, Pep Talk conference, in January 2025.
华盛顿州西雅图/ACCESSWIRE /2024年11月26日/专注于开发基于其专有ADAPTIR和ADAPTIR-FLEX平台技术的新型免疫肿瘤学疗法的临床阶段生物技术公司Aptevo Therapeutics(“Aptevo”)(纳斯达克股票代码:APVO)今天宣布,蛋白质工程高级董事彼得·帕夫利克博士将主持 “双特异和多特异性生物制剂” 会议并发表演讲在剑桥医疗研究所的Pep Talk上发表了题为 “模块化多特异性生物疗法:使用ADAPTIR平台进行快速治疗设计” 的演讲会议,2025 年 1 月。
The presentation will illustrate how Aptevo leverages its proprietary platforms to rapidly advance the development of innovative cancer therapies and use clinical candidates Mipletamig and ALG.APV-527 to exemplify proof of concept for its modular biotherapeutic approach, reducing risk and increasing the likelihood of clinical success for future drug candidates. Aptevo has five compounds in clinical and preclinical development and anticipates introducing a new molecule in early 2025.
该演讲将说明Aptevo如何利用其专有平台快速推进创新癌症疗法的开发,并使用临床候选药物Mipletamig和ALG.APV-527举例说明其模块化生物治疗方法的概念验证,从而降低风险并增加未来候选药物临床成功的可能性。Aptevo有五种化合物正在临床和临床前开发中,预计将在2025年初推出一种新分子。
This leadership opportunity underscores Aptevo's technology and its commitment to driving innovation in functional drug production, creating molecules that perform in the clinic the way they were designed to perform at inception.
这一领导机会凸显了Aptevo的技术及其对推动功能性药物生产创新的承诺,创造出在临床表现与最初设计效果相同的分子。
"Therapeutic candidates are often talked about once they are in human trials, especially when positive results are generated. But the genesis of those drugs and the speed with which they are produced, serves as the backbone of all therapeutic innovation. We work to create molecules that will be safe and tolerable in humans and target cancers as directly and effectively as possible," said Dr. Pavlik. "My presentation will describe how employing modular biotherapeutics can drive pipeline productivity, a critical capability, especially for smaller biotechnology companies navigating a competitive landscape. More specifically, we will explore the power of Aptevo's ADAPTIR and ADAPTIR-FLEX platform technologies, which enable the rapid development of novel multispecific biotherapeutics, accelerating the journey from drug discovery to clinical trials and ultimately patient benefit."
“候选治疗药物一旦进入人体试验,人们经常会谈论它们,尤其是在得出积极结果时。但是,这些药物的起源及其生产速度是所有治疗创新的支柱。我们努力创造对人类安全和可耐受的分子,并尽可能直接有效地靶向癌症,” 帕夫利克博士说。“我的演讲将描述采用模块化生物疗法如何提高管道生产力,这是一项关键能力,特别是对于处于竞争格局中的小型生物技术公司而言。更具体地说,我们将探索Aptevo的ADAPTIR和ADAPTIR-FLEX平台技术的力量,这些技术可以快速开发新的多特异性生物疗法,加快从药物发现到临床试验的旅程,最终使患者受益。”
About Dr. Pavlik
关于帕夫利克博士
Peter Pavlik, PhD, serves as the Senior Director of Protein Engineering at Aptevo Therapeutics. In his career at Aptevo and previously MedImmune/AstraZeneca and Los Alamos National Labs, he has implemented novel technologies to streamline discovery of binding domains and their incorporation into stable and efficacious biotherapeutics. Dr. Pavlik has oversight over all processes currently used at Aptevo which are optimized to multiple areas of drug development from target validation to antibody discovery to IND and to clinic. Peter has a unique understanding of the biopharma industry from the large and small company perspectives.
彼得·帕夫利克博士在Aptevo Therapeutics担任蛋白质工程高级董事。在Aptevo以及之前在Medimmune/阿斯利康和洛斯阿拉莫斯国家实验室任职的职业生涯中,他实施了新技术,以简化结合域的发现及其在稳定有效的生物疗法中的应用。帕夫利克博士负责监督Aptevo目前使用的所有流程,这些流程针对药物开发的多个领域进行了优化,从靶标验证到抗体发现,再到临床试验。Peter 从大小公司的角度对生物制药行业有着独特的理解。
About Aptevo Therapeutics
关于Aptevo Therapeutics
Aptevo Therapeutics Inc. (Nasdaq: APVO) is a clinical-stage biotechnology company focused on developing novel bispecific immunotherapies for the treatment of cancer. The company has two clinical candidates. Mipletamig is currently being evaluated in RAINIER, a Phase 1b/2 trial for the treatment of frontline acute myeloid leukemia in combination with standard of care venetoclax + azacitidine. Mipletamig has orphan status for AML according to the Orphan Drug Act. ALG.APV-527, a bispecific conditional 4-1BB agonist, only active upon simultaneous binding to 4-1BB and 5T4, is being co-developed with Alligator Bioscience and is being evaluated in a Phase 1 clinical trial for the treatment of multiple solid tumor types likely to express 5T4. The Company has three pre-clinical candidates with different mechanisms of action designed to target a range of solid tumors. All pipeline candidates were created from two proprietary platforms, ADAPTIR and ADAPTIR-FLEX. The Aptevo mission is to improve treatment outcomes and transform the lives of cancer patients. For more information, please visit .
Aptevo Therapeutics Inc.(纳斯达克股票代码:APVO)是一家处于临床阶段的生物技术公司,专注于开发用于治疗癌症的新型双特异性免疫疗法。该公司有两个临床候选人。Mipletamig目前正在RAINIER中接受评估。RAINIER是一项1b/2期试验,旨在与标准护理venetoclax + azacitidine联合治疗一线急性髓系白血病。根据《孤儿药法》,Mipletamig拥有反洗钱的孤儿身份。ALG.APV-527是一种双特异性条件性4-1Bb激动剂,只有在与4-1Bb和5T4同时结合时才有效,它正在与Alligator Bioscience共同开发,并且正在一项治疗可能表达5T4的多种实体瘤类型的1期临床试验中进行评估。该公司有三种具有不同作用机制的临床前候选药物,旨在靶向一系列实体瘤。所有候选产品均由两个专有平台创建,即ADAPTIR和ADAPTIR-FLEX。Aptevo的使命是改善治疗结果并改变癌症患者的生活。欲了解更多信息,请访问。
Safe Harbor Statement
安全港声明
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, without limitation, Aptevo's expectations regarding the effectiveness of its ADAPTIR and ADAPTIR-FLEX platform technologies and whether such technologies will accelerate drug discovery and development, statements related to the performance of Aptevo's drug candidates in the clinic and whether such performance will translate into improved patient outcomes, statements related to the progress of and enthusiasm for Aptevo's preclinical and clinical programs, statement related to Aptevo's expectation to add another targeted preclinical asset to the pipeline, statements related to Aptevo's ability to generate stockholder value, whether Aptevo will continue to have momentum in its business in the future, and any other statements containing the words "may," "believes," "expects," "potential," "designed," "engineered," "innovative," "initiate," "allow," "promise," "plans," "will" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on Aptevo's current intentions, beliefs, and expectations regarding future events. Aptevo cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from Aptevo's expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement.
本新闻稿包括1995年《私人证券诉讼改革法》所指的前瞻性陈述。除历史事实陈述以外的所有陈述,包括但不限于Aptevo对其ADAPTIR和ADAPTIR-FLEX平台技术的有效性以及此类技术是否会加速药物发现和开发的预期、与Aptevo候选药物临床表现相关的陈述以及这种表现是否会转化为患者预后改善、与Aptevo临床前和临床项目的进展和热情有关的陈述、与Aptevo临床前和临床项目相关的声明 Vo 的期望为新增另一项有针对性的临床前资产,与Aptevo创造股东价值的能力有关的声明,Aptevo未来是否将继续保持业务势头,以及任何其他包含 “可能”、“相信”、“期望”、“潜力”、“设计”、“设计”、“创新”、“启动”、“允许”、“承诺”、“计划”、“将” 等字样的声明以及类似的表述旨在识别前瞻性陈述。这些前瞻性陈述基于Aptevo当前的意图、信念和对未来事件的期望。Aptevo无法保证任何前瞻性陈述都是准确的。投资者应意识到,如果基本假设证明存在不准确或未知的风险或不确定性,则实际结果可能与Aptevo的预期存在重大差异。因此,提醒投资者不要过分依赖任何前瞻性陈述。
There are several important factors that could cause Aptevo's actual results to differ materially from those indicated by such forward-looking statements, including a deterioration in Aptevo's business or prospects; further assessment of preliminary or interim data or different results from later clinical trials; adverse events and unanticipated problems, adverse developments in clinical development, including unexpected safety issues observed during a clinical trial; adverse developments in the U.S. or global capital markets, credit markets or economies generally; and changes in regulatory, social, macroeconomic, and political conditions. For instance, actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the uncertainties inherent in the initiation, enrollment and maintenance of patients in clinical trials, uncertainties inherent in the results of preliminary or interim data and preclinical and clinical studies being predictive of the results of later-stage clinical trials, the availability and timing of data from ongoing clinical trials, the trial design includes combination therapies that may make it difficult to accurately ascertain the benefits of mipletamig, expectations for the timing and steps required in the regulatory review process, expectations for regulatory approvals, the impact of competitive products, our ability to enter into agreements with strategic partners or raise funds on acceptable terms or at all and other matters that could affect the availability or commercial potential of the Company's product candidates, business or economic disruptions due to catastrophes or other events, including natural disasters or public health crises such as the novel coronavirus (referred to as COVID-19), geopolitical risks, including the current war between Russia and Ukraine as well as the war between Israel and Hamas, and macroeconomic conditions such as rising inflation and interests rates, increased market volatility and decreased consumer confidence. These risks are not exhaustive, Aptevo faces known and unknown risks. Additional risks and factors that may affect results are set forth in Aptevo's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and its subsequent reports on Form 10-Q and current reports on Form 8-K. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from Aptevo's expectations in any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, Aptevo does not assume any obligation to update any forward-looking statement to reflect new information, events, or circumstances.
有几个重要因素可能导致Aptevo的实际结果与此类前瞻性陈述所示结果存在重大差异,包括Aptevo业务或前景恶化;对初步或中期数据的进一步评估或后期临床试验的不同结果;不良事件和意外问题;临床开发的不利发展,包括临床试验期间观察到的意外安全问题;美国或全球资本市场、信贷市场或总体经济的不利发展;以及监管、社会、宏观经济和政治条件的变化。例如,由于各种重要因素,实际结果可能与此类前瞻性陈述所示结果存在重大差异,包括临床试验中患者的启动、入组和维持所固有的不确定性,初步或中期数据以及预测后期临床试验结果的临床前和临床研究结果固有的不确定性,正在进行的临床试验数据的可用性和时机,试验设计包括可能使其成为该结果的联合疗法难以准确确定mipletamig的好处、对监管审查程序所需时间和步骤的预期、对监管部门批准的预期、竞争产品的影响、我们与战略合作伙伴签订协议或以可接受的条件筹集资金的能力,或根本无法确定其他可能影响公司候选产品的可用性或商业潜力的事项,灾难或其他事件(包括自然灾害或公共卫生危机)造成的业务或经济混乱如新型冠状病毒(称为 COVID-19)、地缘政治风险,包括当前的俄罗斯和乌克兰之间的战争以及以色列和哈马斯之间的战争,以及通货膨胀和利率上升、市场波动加剧和消费者信心下降等宏观经济状况。这些风险并非穷尽无遗,Aptevo面临着已知和未知的风险。Aptevo向美国证券交易委员会提交的文件中列出了可能影响业绩的其他风险和因素,包括其截至2023年12月31日财年的10-k表年度报告,以及其后续的10-Q表报告和当前的8-k表报告。上述内容列出了许多(但不是全部)因素,这些因素可能导致实际业绩与Aptevo在任何前瞻性陈述中的预期有所不同。任何前瞻性陈述仅代表截至本新闻稿发布之日,除非法律要求,否则Aptevo不承担任何义务更新任何前瞻性陈述以反映新的信息、事件或情况。
Aptevo Therapeutics
Miriam Weber Miller
Email: IR@apvo.com or millerm@apvo.com
Phone: 206-859-6629
Aptevo 疗法
米里亚姆·韦伯·米勒
电子邮件:IR@apvo.com 或 millerm@apvo.com
电话:206-859-6629
SOURCE: Aptevo Therapeutics
来源:Aptevo Therapeutics